Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Rongrong Cai, Yang Yuan, Jie Sun, Wenqing Xia, Rong Huang, Sai Tian, Xue Dong, Yanjue Shen & Shaohua Wang. (2016) Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis. Expert Opinion on Pharmacotherapy 17:14, pages 1839-1849.
Read now
Read now
James J. DiNicolantonio, Carl J. Lavie, Victor L. Serebruany & James H. O'Keefe. (2013) Statin Wars: The Heavyweight Match-Atorvastatin versus Rosuvastatin for the Treatment of Atherosclerosis, Heart Failure, and Chronic Kidney Disease. Postgraduate Medicine 125:1, pages 7-16.
Read now
Read now
Nariman Nezami, Javid Safa, Behzad Salari, Sona Ghorashi, Khashayar Khosraviani, Sina Davari-Farid, Yashar Hashemi-Aghdam, Ourmaan
Nezami Nargabad & Jafar
Sadegh Tabrizi. (2012) Effect of Lovastatin Therapy and Withdrawal on Serum Uric Acid Level in People With Type 2 Diabetic Nephropathy. Nucleosides, Nucleotides & Nucleic Acids 31:4, pages 353-363.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Michael S Kostapanos, Haralampos J Milionis & Moses S Elisaf. (2010) Current role of statins in the treatment of essential hypertension. Expert Opinion on Pharmacotherapy 11:16, pages 2635-2650.
Read now
Read now
N. Ogata, S. Fujimori, Y. Oka & K. Kaneko. (2010) Effects of Three Strong Statins (Atorvastatin, Pitavastatin, and Rosuvastatin) on Serum Uric Acid Levels in Dyslipidemic Patients. Nucleosides, Nucleotides & Nucleic Acids 29:4-6, pages 321-324.
Read now
Read now
Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2009) JUPITER: major implications for vascular risk assessment. Current Medical Research and Opinion 25:1, pages 133-137.
Read now
Read now
Sandrin C. Bergheanu, Theo Reijmers, Aeilko H. Zwinderman, Ivana Bobeldijk, Raymond Ramaker, An-Ho Liem, Jan van der Greef, Thomas Hankemeier & J. Wouter Jukema. (2008) Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Current Medical Research and Opinion 24:9, pages 2477-2487.
Read now
Read now
Carolyn R Harley, Sanjay K Gandhi, Herbert Heien, Ken McDonough & Stephanie P Nelson. (2008) Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opinion on Pharmacotherapy 9:5, pages 669-676.
Read now
Read now
Kosmas I. Paraskevas & Dimitri P. Mikhailidis. (2008) C-reactive protein (CRP): more than just an innocent bystander?. Current Medical Research and Opinion 24:1, pages 75-78.
Read now
Read now
Robert J. Straka, Muhammad Mamdani, Joep Damen, C. Erik E. Kuntze, Larry Z. Liu, Marc F. Botteman & Michael J. Koren. (2007) Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective. Current Medical Research and Opinion 23:7, pages 1517-1529.
Read now
Read now
Stella S. Daskalopoulou & Dimitri P. Mikhailidis. (2006) Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. Current Medical Research and Opinion 22:10, pages 2037-2039.
Read now
Read now
Articles from other publishers (40)
Nicole Leung, Kevin Yip, Michael H. Pillinger & Michael Toprover. (2022) Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications. Mayo Clinic Proceedings 97:7, pages 1345-1362.
Crossref
Crossref
Ting Cai, Lucy Abel, Oliver Langford, Genevieve Monaghan, Jeffrey K Aronson, Richard J Stevens, Sarah Lay-Flurrie, Constantinos Koshiaris, Richard J McManus, F D Richard Hobbs & James P Sheppard. (2021) Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ, pages n1537.
Crossref
Crossref
Donald J. AbrahamScott D. Edmondson, Duane A. Burnett & Harry R. DavisJrJr. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
36
.
Congcong Ding, Yang Chen, Yumeng Shi, Minghui Li, Lihua Hu, Wei Zhou, Tao Wang, Lingjuan Zhu, Xiao Huang, Huihui Bao & Xiaoshu Cheng. (2020) Association between nontraditional lipid profiles and peripheral arterial disease in Chinese adults with hypertension. Lipids in Health and Disease 19:1.
Crossref
Crossref
Uğur Canpolat, Cem Çöteli & Ahmet Kivrak. (2016) Uric Acid and Contrast-Induced Nephropathy: Diagnostic Marker, Therapeutic Target, or Innocent Bystander?. Angiology 68:7, pages 648-649.
Crossref
Crossref
Qian Ma, Yujie Zhou, Guangyao Zhai, Fei Gao, Linlin Zhang, Jianlong Wang, Qing Yang & Wanjun Cheng. (2015) Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Angiology 67:6, pages 526-535.
Crossref
Crossref
Xiaole Su, Lu Zhang, Jicheng Lv, Jinwei Wang, Wanyin Hou, Xinfang Xie & Hong Zhang. (2016) Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases 67:6, pages 881-892.
Crossref
Crossref
Chern-En Chiang, Jean Ferrières, Nina N Gotcheva, Frederick J Raal, Abdulla Shehab, Jidong Sung, Karin M Henriksson & Michel P Hermans. (2016) Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). Journal of Atherosclerosis and Thrombosis 23:5, pages 567-587.
Crossref
Crossref
Sunghwan SuhChang Hee JungSoon-Jun HongJung-Sun KimByung Ju SongHyun Soon SohnSung Hee Choi. (2016) Economic Evaluation of Rosuvastatin and Atorvastatin for the Treatment of Dyslipidemia from a Korean Health System Perspective. Journal of Lipid and Atherosclerosis 5:1, pages 61.
Crossref
Crossref
Stephen P Adams, Michael Tsang & James M Wright. (2015) Atorvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
Joaquín F. Mould-Quevedo, Magda Vianey Gutiérrez-Ardila, Jaime Eduardo Ordóñez Molina, Brett Pinsky & Nicolás Vargas Zea. (2014) Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia. Value in Health Regional Issues 5, pages 48-57.
Crossref
Crossref
Stephen P Adams, Sarpreet S Sekhon & James M Wright. (2014) Rosuvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
Michael S. Kostapanos, Christos V. Rizos & Moses S. Elisaf. (2014) Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. Drug Safety 37:7, pages 481-500.
Crossref
Crossref
Hisato Takagi, Masao Niwa, Yusuke Mizuno, Hirotaka Yamamoto, Shin-nosuke Goto & Takuya Umemoto. (2013) Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart and Vessels 29:3, pages 287-299.
Crossref
Crossref
Dominika Nowis, Agata Malenda, Karolina Furs, Bozenna Oleszczak, Radoslaw Sadowski, Justyna Chlebowska, Malgorzata Firczuk, Janusz M Bujnicki, Adam D Staruch, Radoslaw Zagozdzon, Eliza Glodkowska-Mrowka, Leszek Szablewski & Jakub Golab. (2014) Statins impair glucose uptake in human cells. BMJ Open Diabetes Research & Care 2:1, pages e000017.
Crossref
Crossref
Abdul Rehman Arshad. (2014) Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial. Journal of Lipids 2014, pages 1-5.
Crossref
Crossref
Ju-Hee Lee, Hyun-Jae Kang, Hyo-Soo Kim, Dae-Won Sohn, Byung-Hee Oh & Young-Bae Park. (2013) Effects of Ezetimibe/Simvastatin 10/20?mg vs. Atorvastatin 20?mg on Apolipoprotein B/Apolipoprotein A1 in Korean Patients with Type 2 Diabetes Mellitus: Results of a Randomized Controlled Trial. American Journal of Cardiovascular Drugs 13:5, pages 343-351.
Crossref
Crossref
Anastazia Kei, Evangelos Liberopoulos, Kostantinos Tellis, Manfredi Rizzo, Moses Elisaf & Alexandros Tselepis. (2013) Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. European Journal of Clinical Investigation 43:7, pages 698-707.
Crossref
Crossref
Niki Katsiki, Asterios Karagiannis, Vasilios G. Athyros & Dimitri P. Mikhailidis. (2013) Hyperuricaemia. Journal of Cardiovascular Medicine 14:6, pages 397-402.
Crossref
Crossref
Elisavet Moutzouri, Evangelos N. Liberopoulos, Matilda Florentin, George Liamis & Moses S. Elisaf. (2012) Effects of Statin Monotherapy Versus Statin Plus Ezetimibe Combination on Serum Uric Acid Levels. Journal of Cardiovascular Pharmacology and Therapeutics 18:1, pages 13-18.
Crossref
Crossref
Stephen P Adams, Michael Tsang & James M Wright. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos & Moses S. Elisaf. (2012) A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 61:7, pages 906-921.
Crossref
Crossref
Hisato Takagi & Takuya Umemoto. (2012) Atorvastatin therapy reduces serum uric acid levels: A meta-analysis of randomized controlled trials. International Journal of Cardiology 157:2, pages 255-257.
Crossref
Crossref
Yongxia Wu, Yan Wang, Chuankai An, Zhe Dong, Hui Liu, Yun Zhang, Mingxiang Zhang & Fengshuang An. (2012) Effects of Rosuvastatin and Atorvastatin on Renal Function. Circulation Journal 76:5, pages 1259-1266.
Crossref
Crossref
Kosmas I. Paraskevas, Dimitri P. Mikhailidis, Nikolaos Roussas & Athanasios D. Giannoukas. (2011) Effect of Antiplatelet Agents, Statins, and Other Drugs on Vascular Access Patency Rates. Angiology 63:1, pages 5-8.
Crossref
Crossref
Hisato Takagi & Takuya Umemoto. (2012) A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein. International Journal of Cardiology 154:1, pages 78-81.
Crossref
Crossref
A. P. Agouridis, V. Tsimihodimos, T. D. Filippatos, A. D. Tselepis & M. S. Elisaf. (2011) High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n‐3 Fatty Acids in Mixed Dyslipidemia. Lipids 46:6, pages 521-528.
Crossref
Crossref
Donald J. AbrahamDuane A. Burnett & Harry R. DavisJr.Jr.. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
303
330
.
Ae-Young Her, Jong-Youn Kim, Seok-Min Kang, Donghoon Choi, Yangsoo Jang, Namsik Chung, Ichiro Manabe & Sang-Hak Lee. (2010) Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism. Journal of Cardiovascular Pharmacology and Therapeutics 15:2, pages 167-174.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis & Moses S. Elisaf. (2010) Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia. American Journal Cardiovascular Drugs 10:1, pages 11-28.
Crossref
Crossref
M. S. Kostapanos, H. J. Milionis, A.-D. Agouridis, C. V. Rizos & M. S. Elisaf. (2009) Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. International Journal of Clinical Practice 63:9, pages 1308-1313.
Crossref
Crossref
M. Rizzo, K. Berneis, G. A. Spinas, G. B. Rini & N. K. Kapur. (2009) Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?. International Journal of Clinical Practice 63:3, pages 478-485.
Crossref
Crossref
Kosmas I. Paraskevas, Nikolaos BessiasTheofanis T. Papas, Vassilios Andrikopoulos & Dimitri P. Mikhailidis. (2008) Is High-sensitivity C-reactive Protein Associated with Subclinical Peripheral Atherosclerosis?. Angiology 60:1, pages 8-11.
Crossref
Crossref
Sarah Hoey. (2008) The therapeutic benefits of rosuvastatin. British Journal of Cardiac Nursing 3:10, pages 482-484.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis & Moses S. Elisaf. (2008) An Overview of the Extra-Lipid Effects of Rosuvastatin. Journal of Cardiovascular Pharmacology and Therapeutics 13:3, pages 157-174.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis, Konstantinos G. Lagos, Christos B. Rizos, Alexandros D. Tselepis & Moses S. Elisaf. (2008) Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. European Journal of Pharmacology 590:1-3, pages 327-332.
Crossref
Crossref
Fergus McTaggart & Peter Jones. (2008) Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit. Cardiovascular Drugs and Therapy 22:4, pages 321-338.
Crossref
Crossref
Michael S. Kostapanos, Christos S. Derdemezis, Theodosios D. Filippatos, Haralampos J. Milionis, Dimitrios N. Kiortsis, Alexandros D. Tselepis & Moses S. Elisaf. (2008) Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. European Journal of Pharmacology 578:2-3, pages 249-252.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis, Theodosios D. Filippatos, Eleni S. Nakou, Eleni T. Bairaktari, Alexandros D. Tselepis & Moses S. Elisaf. (2007) A 12-Week, Prospective, Open-Label Analysis of the Effect of Rosuvastatin on Triglyceride-Rich Lipoprotein Metabolism in Patients with Primary Dyslipidemia. Clinical Therapeutics 29:7, pages 1403-1414.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis, Irene Gazi, Christine Kostara, Eleni T. Bairaktari & Moses Elisaf. (2006) Rosuvastatin Increases α-1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia. The Journal of Clinical Pharmacology 46:11, pages 1337-1343.
Crossref
Crossref